With just one response in 47 patients, Foghorn stops work on lead candidate in advanced eye cancer

Foghorn Ther­a­peu­tics said Wednes­day morn­ing that it was stop­ping fur­ther work on an ex­per­i­men­tal drug for a rare ad­vanced eye can­cer that has spread to oth­er parts of the body.

The Cam­bridge, MA-based biotech was study­ing FHD-286 in 73 metasta­t­ic uveal melanoma pa­tients whose can­cers had still pro­gressed af­ter a me­di­an of two pre­vi­ous ther­a­pies. Across 47 pa­tients who were eval­u­at­ed for re­sponse, just one saw tu­mor le­sions shrink enough to be con­sid­ered a par­tial re­spon­der.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN